Published: September 5, 2026 | Updated: September 5, 2026
Medical Review Notice. This content is reviewed by qualified physicians within our specialist network, including consultants in Hepatology and Regenerative Medicine. We help facilitate access to accredited centers where different regulatory frameworks may apply. Full team profiles are on our Medical Team page; regulatory status is covered in Safety, Risks & Limitations below.
Quick answer
Can stem cell therapy help with liver cirrhosis?
Stem cell therapy for liver cirrhosis — most commonly using mesenchymal stem cells (MSCs) delivered by hepatic artery infusion or IV — is an investigational approach being studied for its potential to support liver function in patients with compensated or decompensated cirrhosis. Multiple small clinical trials and systematic reviews report improvements in markers like
ALB levels and
MELD score, with no serious treatment-related adverse events reported in the pooled data available so far.
It is not an approved cure, is not a replacement for liver transplantation in patients who need one, and outcomes vary by patient.
At Viezec, every liver cirrhosis case begins with a free medical report review by our specialist network, followed by a written treatment plan if a patient may be a reasonable
candidate
for evaluation at an accredited partner hospital. See Safety, Risks & Limitations below for the regulatory context in India.
What is liver cirrhosis?
Liver cirrhosis is the advanced, scarred stage of chronic liver disease, in which healthy liver tissue is progressively replaced by fibrous scar tissue. This disrupts the liver’s normal architecture, restricts blood flow through the organ, and gradually impairs its ability to filter toxins, produce essential proteins, and support digestion.
Cirrhosis is generally classified into two stages:
Compensated cirrhosis — the liver is scarred but still manages to perform most of its functions; many patients have few or no symptoms at this stage.
Decompensated cirrhosis — the liver can no longer keep up with the body’s needs, leading to complications such as ascites (fluid buildup in the abdomen), jaundice, variceal bleeding, or hepatic encephalopathy.
Common underlying causes include chronic hepatitis B or C infection, long-term alcohol use, and non-alcoholic fatty liver disease (NAFLD/MASLD), which has become an increasingly common cause worldwide.
Conventional management focuses on treating the underlying cause, managing complications, and — in advanced, decompensated cases — liver transplantation, which remains the only definitive cure but is limited by donor organ shortages and the need for lifelong immunosuppression. This gap is the main reason regenerative approaches like stem cell therapy are being actively researched as a potential bridge or supportive option.
Causes of liver cirrhosis
Cirrhosis develops gradually, usually over years of ongoing liver injury. The most common underlying causes include:
- Chronic hepatitis B or C infection — long-term viral infection causes persistent liver inflammation that can progress to scarring if untreated.
- Alcohol-related liver disease — sustained heavy alcohol use is one of the leading causes of cirrhosis worldwide.
- Non-alcoholic fatty liver disease (NAFLD/MASLD) — fat accumulation in the liver linked to obesity, insulin resistance, and type 2 diabetes; this has become an increasingly common cause of cirrhosis globally. (See our Type 2 Diabetes stem cell page if metabolic disease is also a factor in your case.)
- Autoimmune hepatitis — the immune system mistakenly attacks liver cells, causing chronic inflammation.
- Biliary causes — conditions such as primary biliary cholangitis or primary sclerosing cholangitis, which damage the bile ducts over time.
- Other causes — certain inherited conditions (e.g., hemochromatosis, Wilson’s disease) and long-term exposure to certain medications or toxins.
Identifying and, where possible, treating the underlying cause is the first step in any cirrhosis management plan — including before any regenerative therapy is considered.
Signs and symptoms of liver cirrhosis
Symptoms often depend on whether cirrhosis is compensated or decompensated.
Early / compensated stage
Symptoms may be mild or absent, but can include:
- Persistent fatigue or weakness
- Loss of appetite and unexplained weight loss
- Mild nausea
- Vague abdominal discomfort
Advanced / decompensated stage
Symptoms tend to be more pronounced and can include:
- Jaundice — yellowing of the skin and eyes
- Ascites — fluid buildup causing abdominal swelling
- Edema — swelling in the legs and ankles
- Easy bruising or bleeding — due to reduced clotting-factor production
- Confusion or memory problems (hepatic encephalopathy) — caused by toxin buildup that the liver can no longer filter effectively
- Vomiting blood or black, tarry stools — which can signal bleeding from esophageal varices and requires urgent medical attention
Anyone experiencing advanced-stage symptoms, particularly vomiting blood, severe confusion, or difficulty breathing, should seek emergency medical care immediately rather than waiting for a scheduled evaluation.
Complications of untreated or advanced cirrhosis
As liver scarring progresses, several serious complications can develop:
- Portal hypertension — increased pressure in the vein carrying blood to the liver, which can lead to enlarged, fragile veins (varices) in the esophagus and stomach.
- Variceal bleeding — a medical emergency caused by rupture of these enlarged veins.
- Hepatic encephalopathy — a decline in brain function caused by the liver’s reduced ability to remove toxins from the blood.
- Ascites and spontaneous bacterial peritonitis — fluid buildup in the abdomen that can become infected.
- Hepatorenal syndrome — progressive kidney dysfunction that can occur alongside advanced liver failure.
- Increased risk of hepatocellular carcinoma (liver cancer) — cirrhosis is one of the strongest risk factors for primary liver cancer, which is why regular monitoring is recommended for cirrhotic patients. (See our Liver Cancer Immunotherapy page if this is a relevant concern for your case.)
These complications are part of why earlier-stage evaluation and monitoring — whether through conventional care or as part of a regenerative-medicine case review — tends to offer more options than waiting until advanced decompensation.
How stem cell therapy is being studied for liver cirrhosis
Most current research uses mesenchymal stem cells (MSCs), typically sourced from bone marrow, adipose tissue, or umbilical cord tissue. MSCs are of interest in liver disease because of several properties observed in laboratory and clinical studies:
- Anti-inflammatory and immunomodulatory signaling — MSCs release cytokines and growth factors that can reduce chronic inflammation within liver tissue.
- Anti-fibrotic effects — some studies suggest MSCs can inhibit hepatic stellate cell activity, the cell type primarily responsible for producing the scar tissue seen in cirrhosis.
- Paracrine support for regeneration — rather than necessarily replacing damaged liver cells directly, MSCs are believed to work mainly by signaling the body’s own regenerative processes, supporting existing hepatocyte (liver cell) function.
- Short-term engraftment — research indicates MSCs are typically present in the target tissue for a limited period, with their benefit understood to come primarily from these paracrine signaling effects rather than long-term cell replacement.
Cells are most commonly delivered by hepatic artery infusion (directly into the blood supply of the liver) or intravenous infusion, with hepatic artery delivery showing more consistent improvements in some pooled analyses.
What the clinical evidence currently shows
It’s important to be direct about where the evidence stands: liver cirrhosis stem cell research is still at an early clinical stage, based on a limited number of small trials, not large-scale, definitive studies. Here’s an honest summary of the most relevant published research:
- Lu W, Qu J, Yan L, et al.
Efficacy and safety of mesenchymal stem cell therapy in liver cirrhosis: a systematic review and meta-analysis.
Stem Cell Research & Therapy. 2023.
View publication
- The assessment of mesenchymal stem cells therapy in acute on chronic liver failure and chronic liver disease:
a systematic review and meta-analysis of randomized controlled clinical trials. 2022.
View publication
- Efficacy and safety of mesenchymal stem cell therapy in acute on chronic liver failure:
a systematic review and meta-analysis of randomized controlled clinical trials.
Stem Cell Research & Therapy. 2025.
View publication
- Rajaram R, Subramani B, Abdullah BJ, Mahadeva S.
Mesenchymal stem cell therapy for advanced liver cirrhosis: A case report.
JGH Open. 2017;1:153-155.
View publication
- Indian Council of Medical Research & Department of Biotechnology.
National Guidelines for Stem Cell Research. New Delhi; October 2017.
View guidelines
All citations are reviewed by our medical team and updated as new research becomes available.
See our full
Research & Publications Hub →
Across this body of research, the consistent themes are:
modest, measurable improvements in liver function markers,
no major safety signal in the studies conducted so far,
and a clear, repeated call from researchers themselves for larger, longer-term randomized trials
before this can be considered an established treatment. We think patients deserve that context clearly, not just the headline that “stem cells help the liver.”
Stem cell therapy vs. conventional treatment
Regenerative approaches are being studied alongside, not as a replacement for, standard cirrhosis management. Here’s how the two currently compare:
The honest takeaway: conventional treatment remains the evidence-backed foundation of cirrhosis care, and stem cell therapy is best understood today as an area of active research that some patients — particularly those who are not transplant candidates — choose to have evaluated as an additional option, not a replacement for standard medical care.
Who might be evaluated as a candidate
Because this remains an investigational, evolving area, candidacy is determined case by case, typically considering:
- Stage of cirrhosis (compensated vs. decompensated) and current liver function scores (Child-Pugh, MELD)
- Underlying cause and whether it is being actively managed (e.g., antiviral therapy for hepatitis, alcohol cessation)
- Presence of complications such as active variceal bleeding, hepatocellular carcinoma, or advanced hepatic encephalopathy, which may affect suitability
- Overall health status and ability to travel and undergo evaluation
- Whether liver transplantation is a more appropriate, definitive option for the patient’s specific situation
This list is for general orientation only — an actual determination requires a full medical report review by qualified specialists.
How the process works at Viezec
- Share your medical reports — liver function tests, imaging, and relevant history, reviewed at no cost.
- Specialist evaluation — our network of hepatology and regenerative medicine consultants reviews your case.
- Written treatment plan — if you may be a reasonable candidate for evaluation, you receive a personalized outline and cost estimate, along with a clear statement of expected limitations.
- Coordination at an accredited partner hospital — treatment planning, GMP-certified cell processing, and hospital coordination handled by your dedicated patient coordinator.
- Follow-up care — post-treatment monitoring and remote guidance after you return home.
Safety, Risks & Limitations
Stem cell therapy for liver cirrhosis remains an evolving and investigational area of regenerative medicine. It is important to understand the potential risks, limitations, and current regulatory status before considering treatment.
- As per the National Guidelines for Stem Cell Research (ICMR & Department of Biotechnology, 2017), stem cell-based interventions — other than hematopoietic stem cell transplantation for approved blood disorder indications — are considered investigational in India and are intended to be conducted within approved, monitored clinical trials, not offered as a guaranteed standard therapy.
- Stem cell therapy for liver cirrhosis is not a proven cure and is not a substitute for liver transplantation in patients who are appropriate transplant candidates.
- Reported side effects in published studies have generally been mild, such as transient fever or injection-site discomfort. However, as with any medical procedure, individual risk depends on overall health, medical history, and the specific protocol used.
- Outcomes vary by patient and are not guaranteed. Some patients may experience measurable improvement in liver function markers, while others may experience limited or no change.
- Insurance typically does not cover investigational stem cell therapy.
- We strongly recommend discussing standard, approved treatment options — including transplant evaluation where relevant — with your local hepatologist alongside any exploration of regenerative approaches.
Important: Stem cell therapy should not be considered a guaranteed treatment or cure for liver cirrhosis. A qualified specialist should review your medical history and determine whether any regenerative approach is appropriate for your individual situation.
Cost considerations
Cost depends on the stage of cirrhosis, the number of infusion sessions recommended, the cell source and processing protocol, and any additional supportive therapies advised by your medical team. Rather than publish a generic price list that doesn’t reflect individual cases, Viezec provides a written estimate after your medical reports are reviewed — so the quote reflects your actual protocol, not an average figure that may not apply to you.
